A detailed history of Frazier Life Sciences Management, L.P. transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 264,377 shares of ACRS stock, worth $764,049. This represents 0.02% of its overall portfolio holdings.

Number of Shares
264,377
Previous 264,377 -0.0%
Holding current value
$764,049
Previous $290,000 2.76%
% of portfolio
0.02%
Previous 0.02%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$7.07 - $17.95 $182,490 - $463,325
-25,812 Reduced 8.89%
264,377 $2.14 Million
Q4 2022

Feb 03, 2023

SELL
$14.33 - $18.37 $1.69 Million - $2.17 Million
-118,140 Reduced 28.93%
290,189 $4.57 Million
Q1 2022

May 16, 2022

BUY
$9.74 - $17.92 $3.98 Million - $7.32 Million
408,329 New
408,329 $7.04 Million

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $193M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Frazier Life Sciences Management, L.P. Portfolio

Follow Frazier Life Sciences Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.